Author ORCID Identifier
Date Available
5-14-2023
Year of Publication
2023
Degree Name
Master of Science (MS)
Document Type
Master's Thesis
College
Pharmacy
Department/School/Program
Pharmaceutical Sciences
First Advisor
Penni Black
Abstract
Recent lung cancer research has led to advancements in molecular immunology, resulting in development of small molecule inhibitors, or immune checkpoint inhibitors, that propagate an anti-tumor T cell response. Despite increased overall and progression-free survival with reduced adverse effects compared to traditional chemotherapy, treating advanced stage lung adenocarcinoma patients remains non-curative, and evidence of non-responders or tumor recurrence to immune checkpoint inhibitor therapy is growing. Also, compared to traditional chemotherapy, there is a lower percentage of patients who respond to small molecule inhibitors. In this analysis of proteomic and genomic data from The Cancer Proteome Atlas and Global Data Commons cancer databases, as well as clinical outcomes data from Phase II POPLAR and Phase III OAK clinical trials, we discuss possible prognostic and predictive factors of immunotherapy in the treatment of advanced non-small-cell lung carcinoma.
Digital Object Identifier (DOI)
https://doi.org/10.13023/etd.2023.224
Recommended Citation
Wuenschel, Mark, "BIOINFORMATIC ANALYSIS OF PROTEOMIC AND GENOMIC DATA FROM NSCLC TUMORS ON PROGNOSTIC AND PREDICTIVE FACTORS OF IMMUNOTHERAPY TREATMENT" (2023). Theses and Dissertations--Pharmacy. 151.
https://uknowledge.uky.edu/pharmacy_etds/151
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Cancer Biology Commons, Other Pharmacy and Pharmaceutical Sciences Commons
